Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;48(1):157-181.
doi: 10.1016/j.rdc.2021.09.006. Epub 2021 Oct 29.

Cardiovascular Health in Pediatric Rheumatologic Diseases

Affiliations
Review

Cardiovascular Health in Pediatric Rheumatologic Diseases

Kaveh Ardalan et al. Rheum Dis Clin North Am. 2022 Feb.

Abstract

Cardiovascular disease risk is evident during childhood for patients with juvenile systemic lupus erythematosus, juvenile dermatomyositis, and juvenile idiopathic arthritis. The American Heart Association defines cardiovascular health as a positive health construct reflecting the sum of protective factors against cardiovascular disease. Disease-related factors such as chronic inflammation and endothelial dysfunction increase cardiovascular disease risk directly and through bidirectional relationships with poor cardiovascular health factors. Pharmacologic and nonpharmacologic interventions to improve cardiovascular health and long-term cardiovascular outcomes in children with rheumatic disease are needed.

Keywords: Cardiovascular disease; Cardiovascular health; Juvenile dermatomyositis; Juvenile idiopathic arthritis; Pediatric rheumatology; Systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

Disclosure Dr K. Ardalan receives salary support from Cure JM Foundation to assist with clinical trial design with ReveraGen BioPharma but does not receive any funding or compensation from ReveraGen BioPharma; he also receives salary/grant support from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Rheumatology Research Foundation. Dr D.M. Lloyd-Jones has no commercial or financial conflicts to disclose. Dr L.E. Schanberg receives salary support from CARRA, Inc; DSMB member for Sanofi and UCB; grant support from PCORI and BMS.

MeSH terms